United Therapeutics (NASDAQ:UTHR) Price Target Raised to $600.00

United Therapeutics (NASDAQ:UTHR) had its price target lifted by HC Wainwright from $525.00 to $600.00 in a research report report published on Thursday, MarketBeat Ratings reports. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages have also commented on UTHR. Oppenheimer lifted their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday. Jefferies Financial Group reaffirmed a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. TD Cowen boosted their price target on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research note on Wednesday. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Bank of America reaffirmed a “neutral” rating on shares of United Therapeutics in a research note on Wednesday. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $533.55.

United Therapeutics Price Performance

UTHR stock opened at $503.90 on Thursday. The company has a 50 day moving average price of $484.38 and a 200 day moving average price of $446.93. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $537.19. The stock has a market capitalization of $22.09 billion, a PE ratio of 18.06, a price-to-earnings-growth ratio of 1.79 and a beta of 0.85.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period last year, the firm earned $6.19 EPS. As a group, equities analysts expect that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $479.91, for a total value of $10,797,975.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 21,000 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $479.99, for a total transaction of $10,079,790.00. Following the completion of the sale, the chief financial officer owned 8,142 shares of the company’s stock, valued at approximately $3,908,078.58. This represents a 72.06% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 407,954 shares of company stock valued at $197,601,528. Corporate insiders own 10.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AXQ Capital LP lifted its holdings in shares of United Therapeutics by 495.4% during the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after purchasing an additional 3,235 shares in the last quarter. AE Wealth Management LLC increased its stake in United Therapeutics by 396.3% during the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC raised its holdings in United Therapeutics by 194.7% during the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after buying an additional 2,975 shares during the period. Optimize Financial Inc bought a new position in United Therapeutics in the third quarter valued at approximately $444,000. Finally, Simplify Asset Management Inc. bought a new position in United Therapeutics in the third quarter valued at approximately $8,351,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 outperformance and growth target — UTHR beat EPS expectations (reported strength in Tyvaso DPI sales) and management is targeting roughly a $4B revenue run‑rate by 2027 as several late‑stage product launches approach; this underpins the recent rally and longer‑term growth thesis. Read More.
• Positive Sentiment: Analysts lifting targets — Multiple firms raised price targets (examples: H.C. Wainwright, RBC, Oppenheimer), which supports further upside and institutional interest. Read More.
• Positive Sentiment: Bullish options flow — Unusually large call buying around the print suggests traders are positioning for further upside or volatility in the short term. Read More.
• Neutral Sentiment: Technical/relative strength recognition — UTHR earned a high RS rating (91), signaling market leadership but not guaranteeing direction near term. Read More.
• Neutral Sentiment: Mixed analyst views remain — while many bumped targets, some firms kept Hold/equal‑weight ratings, leaving near‑term consensus mixed. Read More.
• Negative Sentiment: Revenue missed consensus — Q4 revenue came in below Street estimates, which sparked an earlier pullback and is a reminder top‑line execution matters for the multiple. Read More.
• Negative Sentiment: Insider selling — The COO and a director disclosed multi‑lot sales in February (COO sale worth several million and director sales disclosed), which can create investor concern about near‑term insider conviction. Read More. Read More.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.